Predictive biomarkers for immunotherapy in nasopharyngeal carcinoma: from tumor microenvironment to macroenvironment

Abstract

The introduction of PD-1 blockades to chemotherapy and radiotherapy has shown promising outcomes in patients with nasopharyngeal carcinoma, but anti-PD-1 therapies are only effective in a small proportion of patients, indicating the need for reliable predictive biomarkers of benefit from immunotherapy. Here, we summarized recent advances in immunotherapy for nasopharyngeal carcinoma and studies on potential predictors that correlated with treatment response or long-term survival after immunotherapy, including biomarkers in both the tumor microenvironment and the tumor macroenvironment. Some of these biomarkers have been validated as truly predictive of immunotherapy benefit using cohorts from randomized controlled trials, while others still require further validation of their predictive value. We also summarized the challenges and future directions of biomarker studies, hopefully facilitating the development of predictive biomarkers for immunotherapy that can eventually enter clinical practice.

Keywords

nasopharyngeal carcinoma / immunotherapy / predictive biomarker

References

[1] Chen YP , Chan ATC , Le QT , Blanchard P , Sun Y , Ma J . Nasopharyngeal carcinoma. Lancet 2019; 394(10192): 64–80

[2] Badoual C . Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Oropharynx and Nasopharynx. Head Neck Pathol 2022; 16(1): 19–30

[3] Xu ZJ , Zheng RS , Zhang SW , Zou XN , Chen WQ . Nasopharyngeal carcinoma incidence and mortality in China in 2009. Chin J Cancer 2013; 32(8): 453–460

[4] Bray F , Laversanne M , Sung H , Ferlay J , Siegel RL , Soerjomataram I , Jemal A . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3): 229–263

[5] Han B , Zheng R , Zeng H , Wang S , Sun K , Chen R , Li L , Wei W , He J . Cancer incidence and mortality in China, 2022. J Natl Cancer Cent 2024; 4(1): 47–53

[6] Chang ET , Ye W , Zeng YX , Adami HO . The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2021; 30(6): 1035–1047

[7] Filho AM , Laversanne M , Ferlay J , Colombet M , Pineros M , Znaor A , Parkin DM , Soerjomataram I , Bray F . The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer 2025; 156(7): 1336–1346

[8] Li WZ , Lv SH , Liu GY , Liang H , Xia WX , Xiang YQ . Age-dependent changes of gender disparities in nasopharyngeal carcinoma survival. Biol Sex Differ 2021; 12(1): 18

[9] Wong KCW , Hui EP , Lo KW , Lam WKJ , Johnson D , Li L , Tao Q , Chan KCA , To KF , King AD , Ma BBY , Chan ATC . Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol 2021; 18(11): 679–695

[10] Su ZY , Siak PY , Leong CO , Cheah SC . The role of Epstein-Barr virus in nasopharyngeal carcinoma. Front Microbiol 2023; 14: 1116143

[11] Pan JJ , Ng WT , Zong JF , Lee SW , Choi HC , Chan LL , Lin SJ , Guo QJ , Sze HC , Chen YB , Xiao YP , Kan WK , O’Sullivan B , Xu W , Le QT , Glastonbury CM , Colevas AD , Weber RS , Lydiatt W , Shah JP , Lee AW . Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer 2016; 122(21): 3307–3315

[12] Yang Q , Cao SM , Guo L , Hua YJ , Huang PY , Zhang XL , Lin M , You R , Zou X , Liu YP , Xie YL , Wang ZQ , Mai HQ , Chen QY , Tang LQ , Mo HY , Cao KJ , Qian CN , Zhao C , Xiang YQ , Zhang XP , Lin ZX , Li WX , Liu Q , Li JB , Ling L , Guo X , Hong MH , Chen MY . Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer 2019; 119: 87–96

[13] Wang YQ , Zhang Y , Jiang W , Chen YP , Xu SY , Liu N , Zhao Y , Li L , Lei Y , Hong XH , Liang YL , Li JY , Zhang LL , Yun JP , Sun Y , Li YQ , Ma J . Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis. J Immunother Cancer 2019; 7(1): 298

[14] Mai HQ , Chen QY , Chen D , Hu C , Yang K , Wen J , Li J , Shi Y , Jin F , Xu R , Pan J , Qu S , Li P , Hu C , Liu YC , Jiang Y , He X , Wang HM , Lim WT , Liao W , He X , Chen X , Wang S , Yuan X , Li Q , Lin X , Jing S , Chen Y , Lu Y , Hsieh CY , Yang MH , Yen CJ , Samol J , Luo X , Wang X , Tang X , Feng H , Yao S , Keegan P , Xu RH . Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: The JUPITER-02 Randomized Clinical Trial. JAMA 2023; 330(20): 1961–1970

[15] Peng G , Wang T , Yang KY , Zhang S , Zhang T , Li Q , Han J , Wu G . A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 2012; 104(3): 286–293

[16] Lewis GD , Holliday EB , Kocak-Uzel E , Hernandez M , Garden AS , Rosenthal DI , Frank SJ . Intensity-modulated proton therapy for nasopharyngeal carcinoma: decreased radiation dose to normal structures and encouraging clinical outcomes. Head Neck 2016; 38(Suppl 1): E1886–E1895

[17] Hu J , Bao C , Gao J , Guan X , Hu W , Yang J , Hu C , Kong L , Lu JJ . Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: initial results. Cancer 2018; 124(11): 2427–2437

[18] Wu LR , Liu YT , Jiang N , Fan YX , Wen J , Huang SF , Guo WJ , Bian XH , Wang FJ , Li F , Song D , Wu JF , Jiang XS , Liu JY , He X . Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: an analysis of 614 patients from a single center. Oral Oncol 2017; 69: 26–32

[19] Chen YP , Ismaila N , Chua MLK , Colevas AD , Haddad R , Huang SH , Wee JTS , Whitley AC , Yi JL , Yom SS , Chan ATC , Hu CS , Lang JY , Le QT , Lee AWM , Lee N , Lin JC , Ma B , Morgan TJ , Shah J , Sun Y , Ma J . Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II–IVA nasopharyngeal carcinoma: CSCO and ASCO Guideline. J Clin Oncol 2021; 39(7): 840–859

[20] Chen L , Hu CS , Chen XZ , Hu GQ , Cheng ZB , Sun Y , Li WX , Chen YY , Xie FY , Liang SB , Chen Y , Xu TT , Li B , Long GX , Wang SY , Zheng BM , Guo Y , Sun Y , Mao YP , Tang LL , Chen YM , Liu MZ , Ma J . Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012; 13(2): 163–171

[21] Chen L , Hu CS , Chen XZ , Hu GQ , Cheng ZB , Sun Y , Li WX , Chen YY , Xie FY , Liang SB , Chen Y , Xu TT , Li B , Long GX , Wang SY , Zheng BM , Guo Y , Sun Y , Mao YP , Tang LL , Chen YM , Liu MZ , Ma J . Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase 3 multicentre randomised controlled trial. Eur J Cancer 2017; 75: 150–158

[22] Cao SM , Yang Q , Guo L , Mai HQ , Mo HY , Cao KJ , Qian CN , Zhao C , Xiang YQ , Zhang XP , Lin ZX , Li WX , Liu Q , Qiu F , Sun R , Chen QY , Huang PY , Luo DH , Hua YJ , Wu YS , Lv X , Wang L , Xia WX , Tang LQ , Ye YF , Chen MY , Guo X , Hong MH . Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer 2017; 75: 14–23

[23] Sun Y , Li WF , Chen NY , Zhang N , Hu GQ , Xie FY , Sun Y , Chen XZ , Li JG , Zhu XD , Hu CS , Xu XY , Chen YY , Hu WH , Guo L , Mo HY , Chen L , Mao YP , Sun R , Ai P , Liang SB , Long GX , Zheng BM , Feng XL , Gong XC , Li L , Shen CY , Xu JY , Guo Y , Chen YM , Zhang F , Lin L , Tang LL , Liu MZ , Ma J . Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 2016; 17(11): 1509–1520

[24] Peng H , Chen L , Zhang J , Li WF , Mao YP , Zhang Y , Liu LZ , Tian L , Lin AH , Sun Y , Ma J . Induction chemotherapy improved long-term outcomes of patients with locoregionally advanced nasopharyngeal carcinoma: a propensity matched analysis of 5-year survival outcomes in the era of intensity-modulated radiotherapy. J Cancer 2017; 8(3): 371–377

[25] Zhang Y , Chen L , Hu GQ , Zhang N , Zhu XD , Yang KY , Jin F , Shi M , Chen YP , Hu WH , Cheng ZB , Wang SY , Tian Y , Wang XC , Sun Y , Li JG , Li WF , Li YH , Tang LL , Mao YP , Zhou GQ , Sun R , Liu X , Guo R , Long GX , Liang SQ , Li L , Huang J , Long JH , Zang J , Liu QD , Zou L , Su QF , Zheng BM , Xiao Y , Guo Y , Han F , Mo HY , Lv JW , Du XJ , Xu C , Liu N , Li YQ , Chua MLK , Xie FY , Sun Y , Ma J . Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 2019; 381(12): 1124–1135

[26] Chen YP , Liu X , Zhou Q , Yang KY , Jin F , Zhu XD , Shi M , Hu GQ , Hu WH , Sun Y , Wu HF , Wu H , Lin Q , Wang H , Tian Y , Zhang N , Wang XC , Shen LF , Liu ZZ , Huang J , Luo XL , Li L , Zang J , Mei Q , Zheng BM , Yue D , Xu J , Wu SG , Shi YX , Mao YP , Chen L , Li WF , Zhou GQ , Sun R , Guo R , Zhang Y , Xu C , Lv JW , Guo Y , Feng HX , Tang LL , Xie FY , Sun Y , Ma J . Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 2021; 398(10297): 303–313

[27] Wilfahrt D , Delgoffe GM . Metabolic waypoints during T cell differentiation. Nat Immunol 2024; 25(2): 206–217

[28] Kraehenbuehl L , Weng CH , Eghbali S , Wolchok JD , Merghoub T . Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol 2022; 19(1): 37–50

[29] Jiang X , Wang J , Deng X , Xiong F , Ge J , Xiang B , Wu X , Ma J , Zhou M , Li X , Li Y , Li G , Xiong W , Guo C , Zeng Z . Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer 2019; 18(1): 10

[30] Lu L , Zhan M , Li XY , Zhang H , Dauphars DJ , Jiang J , Yin H , Li SY , Luo S , Li Y , He YW . Clinically approved combination immunotherapy: current status, limitations, and future perspective. Curr Res Immunol 2022; 3: 118–127

[31] Wolchok J . Putting the immunologic brakes on cancer. Cell 2018; 175(6): 1452–1454

[32] Mai HQ , Chen QY , Chen D , Hu C , Yang K , Wen J , Li J , Shi YR , Jin F , Xu R , Pan J , Qu S , Li P , Hu C , Liu YC , Jiang Y , He X , Wang HM , Lim WT , Liao W , He X , Chen X , Liu Z , Yuan X , Li Q , Lin X , Jing S , Chen Y , Lu Y , Hsieh CY , Yang MH , Yen CJ , Samol J , Feng H , Yao S , Keegan P , Xu RH . Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med 2021; 27(9): 1536–1543

[33] Yang Y , Qu S , Li J , Hu C , Xu M , Li W , Zhou T , Shen L , Wu H , Lang J , Hu G , Luo Z , Fu Z , Qu S , Feng W , Chen X , Lin S , Zhang W , Li X , Sun Y , Lin Z , Lin Q , Lei F , Long J , Hong J , Huang X , Zeng L , Wang P , He X , Zhang B , Yang Q , Zhang X , Zou J , Fang W , Zhang L . Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2021; 22(8): 1162–1174

[34] Yang Y , Pan J , Wang H , Zhao Y , Qu S , Chen N , Chen X , Sun Y , He X , Hu C , Lin L , Yu Q , Wang S , Wang G , Lei F , Wen J , Yang K , Lin Z , Guo Y , Chen S , Huang X , Wu Y , Liang L , Chen C , Bai F , Ma X , Zhang Y , Leaw S , Zhang L , Fang W . Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell 2023; 41(6): 1061–1072.e4

[35] Shi Y , Qin X , Peng X , Zeng A , Li J , Chen C , Qiu S , Pan S , Zheng Y , Cai J , Chen X , Qu S , Lin L , Huang J , Wu H , Lu Y , Wang W , Hu C , He X , Yu Z , Liu X , Xie B , Liu A , Hu G , Jing S , Zhang Q , Guo R , Li Q , Hong J , Jin F , Meng J , Shi J , Wang P , Cui J , Yang K , Zhang X , Li X , Shen L , He Y , Zhai L , Sun X , Ge J , Qing Y , Zong D . Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study. Lancet Reg Health West Pac 2023; 31: 100617

[36] Wang FH , Wei XL , Feng J , Li Q , Xu N , Hu XC , Liao W , Jiang Y , Lin XY , Zhang QY , Yuan XL , Huang HX , Chen Y , Dai GH , Shi JH , Shen L , Yang SJ , Shu YQ , Liu YP , Wang W , Wu H , Feng H , Yao S , Xu RH . Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol 2021; 39(7): 704–712

[37] Liu X , Shen H , Zhang L , Huang W , Zhang S , Zhang B . Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma. NPJ Precis Oncol 2024; 8(1): 101

[38] Chan ATC , Lee VHF , Hong RL , Ahn MJ , Chong WQ , Kim SB , Ho GF , Caguioa PB , Ngamphaiboon N , Ho C , Aziz M , Ng QS , Yen CJ , Soparattanapaisarn N , Ngan RK , Kho SK , Tiambeng MLA , Yun T , Sriuranpong V , Algazi AP , Cheng A , Massarelli E , Swaby RF , Saraf S , Yuan J , Siu LL . Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. Ann Oncol 2023; 34(3): 251–261

[39] Jung HA , Park KU , Cho S , Lim J , Lee KW , Hong MH , Yun T , An HJ , Park WY , Pereira S , Ock CY , Keam B . A phase II study of nivolumab plus gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma (KCSG HN17–11). Clin Cancer Res 2022; 28(19): 4240–4247

[40] Lim DW , Kao HF , Suteja L , Li CH , Quah HS , Tan DS , Tan SH , Tan EH , Tan WL , Lee JN , Wee FY , Jain A , Goh BC , Chua MLK , Liao BC , Ng QS , Hong RL , Ang MK , Yeong JP , Iyer NG . Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma. Nat Commun 2023; 14(1): 2781

[41] Ruan DY , Wei XL , Liu FR , Hu XC , Zhang J , Ji DM , Huang DZ , Zhao YQ , Pan HM , Liao WJ , Yang KY , Xu N , Lu XX , Chen YL , Zhang W , Zhou H , Zhao HY , Xu RH . The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study. J Hematol Oncol 2024; 17(1): 118

[42] Ding X , Zhang WJ , You R , Zou X , Wang ZQ , Ouyang YF , Peng L , Liu YP , Duan CY , Yang Q , Lin C , Xie YL , Chen SY , Liu YL , Gu CM , Xie RQ , Huang PY , Hong MH , Hua YJ , Chen MY . Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase ii study. J Clin Oncol 2023; 41(14): 2571–2582

[43] Lu N , Jiang YF , Xia WX , Huang Y , Xie CM , Xu C , Ye YF , Liu GY , Bei WX , Ke LR , Li WZ , Zhang C , Wang X , Liu Q , Chen X , Chen ZX , Xie C , Liang H , Xiang YQ . Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study. EClinicalMedicine 2023; 62: 102136

[44] Chong WQ , Low JL , Tay JK , Le TBU , Goh GS , Sooi K , Teo HL , Cheo SW , Wong RT , Samol J , Lim MY , Li H , Shirgaonkar N , Chia S , Wang L , Gopinathan A , Eu DK , Tsang RK , Loh KS , Toh HC , Syn N , Kong LR , Dasgupta R , Tai BC , Lim YC , Goh BC . Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial. Lancet Oncol 2025; 26(2): 175–186

[45] Yuan L , Jia GD , Lv XF , Xie SY , Guo SS , Lin DF , Liu LT , Luo DH , Li YF , Deng SW , Guo L , Zeng MS , Cai XY , Liu SL , Sun XS , Li XY , Li SC , Chen QY , Tang LQ , Mai HQ . Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial. Nat Commun 2023; 14(1): 4893

[46] Ruan D , Han F , Zhou Y , Wang F , Tang LQ , Li Z , Chen QY , Chen C , Lin J , Liu FR , Xiao F , Shi Y , Xu RH . Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors. J Clin Oncol 2024; 42(16 suppl): 6013

[47] Colevas AD , Siu LL , Lim DWT , Gao B , Rojkjaer L , Katkov A , Katz Y , Ma B . A phase 1b/2 study of nanatinostat and valganciclovir in patients with advanced Epstein-Barr virus positive (EBV⁺) solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC). J Clin Oncol 2022; 40(16 suppl): TPS6107

[48] Colevas AD , Cohen RB , Park JC , Pfister DG , Massarelli E , Li Z , Xing B , Dinavahi R , Mehta A . Safety of tabelecleucel with pembrolizumab in recurrent/metastatic Epstein–Barr virus-associated nasopharyngeal carcinoma. J Clin Oncol 2024; 42(16 suppl): 6096

[49] Chen QY , Mai HQ , Tang LQ , Luo M , Zhao C , Mo HY , Sun R , Luo DH , Wang L , Guo SS , Xie S , Li SC , Liu SL , Li XY , Peng JY , Qiu HZ , Sun XS , Liu L . Neoadjuvant chemotherapy plus tislelizumab followed by concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a single-arm, phase II trial. J Clin Oncol 2022; 40(16 suppl): 6068

[50] Hui EP , Ma B , Lim DWT , Lam WJ , Soong YL , Li L , Wong KCW , Lam D , Mok F , Tong M , Poon DM , Wong CH , Mo F , King AD , Lo KW , Chan JYK , Chan KA , Chan ATC . NEOSPACE trial: neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC). J Clin Oncol 2023; 41(16 suppl): 6010

[51] Wang X , Han F , Huang Y , Xu C , Mao Y , Lin L , Chen Y , Chen C . Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC), a prospective, single-armed phase II trial. Ann Oncol 2023; 34(suppl 2): S581

[52] Xu C , Zhou GQ , Li WF , Hu DS , Chen XZ , Lin SJ , Jin F , Huang XQ , Peng G , Huang J , Wu Y , Tao CJ , Li JB , Lin AH , Zhao HY , Hong SB , Huang HL , Tang LL , Peng YL , Shi KF , Chen L , Qi LP , Yang KY , Shen LF , Sun Y , Ma J . Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: a multicenter phase 2 PLATINUM trial. Cancer Cell 2025; 43(5): 925–936. e4

[53] Liu X , Zhang Y , Yang KY , Zhang N , Jin F , Zou GR , Zhu XD , Xie FY , Liang XY , Li WF , He ZY , Chen NY , Hu WH , Wu HJ , Shi M , Zhou GQ , Mao YP , Guo R , Sun R , Huang J , Liang SQ , Wu WL , Su Z , Li L , Ai P , He YX , Zang J , Chen L , Lin L , Huang SH , Xu C , Lv JW , Li YQ , Hong SB , Jie YS , Li H , Huang SW , Liang YL , Wang YQ , Peng YL , Zhu JH , Zang SB , Liu SR , Lin QG , Li HJ , Tian L , Liu LZ , Zhao HY , Lin AH , Li JB , Liu N , Tang LL , Chen YP , Sun Y , Ma J . Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 2024; 403(10445): 2720–2731

[54] Liang YL , Liu X , Shen LF , Hu GY , Zou GR , Zhang N , Chen CB , Chen XZ , Zhu XD , Yuan YW , Yang KY , Jin F , Hu WH , Xie FY , Huang Y , Han F , Tang LL , Mao YP , Lu LX , Sun R , He YX , Zhou YY , Long GX , Tang J , Chen LS , Zong JF , Jin T , Li L , Lin J , Huang J , Gong XY , Zhou GQ , Chen L , Li WF , Chen YP , Xu C , Lin L , Huang SH , Huang SW , Wang YQ , Huang CL , Feng HX , Hou M , Chen CH , Zheng SF , Li YQ , Hong SB , Jie YS , Li H , Yun JP , Zang SB , Liu SR , Lin QG , Li HJ , Tian L , Liu LZ , Zhao HY , Li JB , Lin AH , Liu N , Zhang Y , Guo R , Ma J , Sun Y . Adjuvant PD-1 blockade with camrelizumab for nasopharyngeal carcinoma: the DIPPER randomized clinical trial. JAMA 2025; 333(18): 1589

[55] Liu SL , Li XY , Yang JH , Wen DX , Guo SS , Liu LT , Li YF , Luo MJ , Xie SY , Liang YJ , Sun XS , Yang ZC , Lv XF , Luo DH , Li JB , Liu Q , Wang P , Guo L , Mo HY , Sun R , Yang Q , Lan KQ , Jia GD , Li R , Zhao C , Xu RH , Chen QY , Tang LQ , Mai HQ . Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2024; 25(12): 1563–1575

[56] Mai HQ , Liu SL , Chen QY , Tang LQ , Jin F , Guo L , Luo H , Hu Y , Liu H , Liang JH , Zhao C , Luo DH , Mo HY , Guo SS , Liu LT , Li JB , Wang L , Sun XS , Li XY , Wang P . Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial. J Clin Oncol 2024; 42(16 suppl): 6001

[57] Cai M , Wang Y , Ma H , Yang L , Xu Z . Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma. Cancer Treat Rev 2024; 131: 102840

[58] Kang M , Yang K , Lu Y , Yu J , Ma D , Tang S , Gao J , Zhang T , Yang Z , Lv J , Qin Y , Wu F , Ruan L , Liu K , Dong H , Meng Z , Qin Y , Wang R . Induction chemotherapy followed by concurrent chemoradiotherapy combined with toripalimab and Endostar in high-risk locally advanced nasopharyngeal carcinoma: a multicenter, randomized, phase 2 trial. J Clin Oncol 2024; 42(16 suppl): 6086

[59] Garon EB , Rizvi NA , Hui R , Leighl N , Balmanoukian AS , Eder JP , Patnaik A , Aggarwal C , Gubens M , Horn L , Carcereny E , Ahn MJ , Felip E , Lee JS , Hellmann MD , Hamid O , Goldman JW , Soria JC , Dolled-Filhart M , Rutledge RZ , Zhang J , Lunceford JK , Rangwala R , Lubiniecki GM , Roach C , Emancipator K , Gandhi L , Investigators K . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372(21): 2018–2028

[60] Burtness B , Harrington KJ , Greil R , Soulieres D , Tahara M , de Castro G Jr , Psyrri A , Baste N , Neupane P , Bratland A , Fuereder T , Hughes BGM , Mesia R , Ngamphaiboon N , Rordorf T , Wan Ishak WZ , Hong RL , Gonzalez Mendoza R , Roy A , Zhang Y , Gumuscu B , Cheng JD , Jin F , Rischin D; KEYNOTE-048 Investigators . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394(10212): 1915–1928

[61] Rimm DL , Han G , Taube JM , Yi ES , Bridge JA , Flieder DB , Homer R , West WW , Wu H , Roden AC , Fujimoto J , Yu H , Anders R , Kowalewski A , Rivard C , Rehman J , Batenchuk C , Burns V , Hirsch FR , Wistuba A II . Prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol 2017; 3(8): 1051–1058

[62] Gaule P , Smithy JW , Toki M , Rehman J , Patell-Socha F , Cougot D , Collin P , Morrill P , Neumeister V , Rimm DL . A quantitative comparison of antibodies to programmed cell death 1 ligand 1. JAMA Oncol 2017; 3(2): 256–259

[63] Jardim DL , Goodman A , de Melo Gagliato D , Kurzrock R . The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell 2021; 39(2): 154–173

[64] Jiang N , Liu N , Yang F , Zhou Q , Cui R , Jiang W , He Q , Li W , Guo Y , Zeng J , Yun J , Chen X , Zhou B , Sun Y , Wang H , Chen ZG , Ma J . Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma. Oncol Rep 2014; 32(4): 1661–1669

[65] Yarchoan M , Albacker LA , Hopkins AC , Montesion M , Murugesan K , Vithayathil TT , Zaidi N , Azad NS , Laheru DA , Frampton GM , Jaffee EM . PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 2019; 4(6): e126908

[66] Fang W , Yang Y , Ma Y , Hong S , Lin L , He X , Xiong J , Li P , Zhao H , Huang Y , Zhang Y , Chen L , Zhou N , Zhao Y , Hou X , Yang Q , Zhang L . Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol 2018; 19(10): 1338–1350

[67] Wang Y , Lai X , Wang J , Xu Y , Zhang X , Zhu X , Liu Y , Shao Y , Zhang L , Fang W . TMBcat: a multi-endpoint p-value criterion on different discrepancy metrics for superiorly inferring tumor mutation burden thresholds. Front Immunol 2022; 13: 995180

[68] Budczies J , Kazdal D , Menzel M , Beck S , Kluck K , Altburger C , Schwab C , Allgauer M , Ahadova A , Kloor M , Schirmacher P , Peters S , Kramer A , Christopoulos P , Stenzinger A . Tumour mutational burden: clinical utility, challenges and emerging improvements. Nat Rev Clin Oncol 2024; 21(10): 725–742

[69] Su X , Jin H , Wang J , Lu H , Gu T , Gao Z , Li M . Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers. Aging (Albany NY) 2022; 14(10): 4586–4605

[70] Taieb J , Svrcek M , Cohen R , Basile D , Tougeron D , Phelip JM . Deficient mismatch repair/microsatellite unstable colorectal cancer: diagnosis, prognosis and treatment. Eur J Cancer 2022; 175: 136–157

[71] Chalmers ZR , Connelly CF , Fabrizio D , Gay L , Ali SM , Ennis R , Schrock A , Campbell B , Shlien A , Chmielecki J , Huang F , He Y , Sun J , Tabori U , Kennedy M , Lieber DS , Roels S , White J , Otto GA , Ross JS , Garraway L , Miller VA , Stephens PJ , Frampton GM . Analysis of 100, 000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017; 9(1): 34

[72] Zhao L , Liao X , Hong G , Zhuang Y , Fu K , Chen P , Wang Y , Chen H , Lin Q . Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma. Cancer Manag Res 2019; 11: 1631–1640

[73] Chang AMV , Chiosea SI , Altman A , Pagdanganan HA , Ma C . Programmed death-ligand 1 expression, microsatellite instability, Epstein-Barr virus, and human papillomavirus in nasopharyngeal carcinomas of patients from the Philippines. Head Neck Pathol 2017; 11(2): 203–211

[74] Yang Y , Zhou T , Chen X , Li J , Pan J , He X , Lin L , Shi YR , Feng W , Xiong J , Yang K , Yu Q , Zhang Q , Hu D , Sun Y , Hu G , Li P , Shen L , Lin Q , Zhang B , Qu X , Zou J , Zhang L , Fang W , Zhao Y . Efficacy, safety, and biomarker analysis of camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN study). J Immunother Cancer 2021; 9(12): e003790

[75] Huang SW , Jiang W , Xu S , Zhang Y , Du J , Wang YQ , Yang KY , Zhang N , Liu F , Zou GR , Jin F , Wu HJ , Zhou YY , Zhu XD , Chen NY , Xu C , Qiao H , Liu N , Sun Y , Ma J , Liang YL , Liu X . Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials. Signal Transduct Target Ther 2024; 9(1): 285

[76] Helmink BA , Reddy SM , Gao J , Zhang S , Basar R , Thakur R , Yizhak K , Sade-Feldman M , Blando J , Han G , Gopalakrishnan V , Xi Y , Zhao H , Amaria RN , Tawbi HA , Cogdill AP , Liu W , LeBleu VS , Kugeratski FG , Patel S , Davies MA , Hwu P , Lee JE , Gershenwald JE , Lucci A , Arora R , Woodman S , Keung EZ , Gaudreau PO , Reuben A , Spencer CN , Burton EM , Haydu LE , Lazar AJ , Zapassodi R , Hudgens CW , Ledesma DA , Ong S , Bailey M , Warren S , Rao D , Krijgsman O , Rozeman EA , Peeper D , Blank CU , Schumacher TN , Butterfield LH , Zelazowska MA , McBride KM , Kalluri R , Allison J , Petitprez F , Fridman WH , Sautes-Fridman C , Hacohen N , Rezvani K , Sharma P , Tetzlaff MT , Wang L , Wargo JA . B cells and tertiary lymphoid structures promote immunotherapy response. Nature 2020; 577(7791): 549–555

[77] Cabrita R , Lauss M , Sanna A , Donia M , Skaarup Larsen M , Mitra S , Johansson I , Phung B , Harbst K , Vallon-Christersson J , van Schoiack A , Lovgren K , Warren S , Jirstrom K , Olsson H , Pietras K , Ingvar C , Isaksson K , Schadendorf D , Schmidt H , Bastholt L , Carneiro A , Wargo JA , Svane IM , Jonsson G . Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 2020; 577(7791): 561–565

[78] Petitprez F , de Reynies A , Keung EZ , Chen TW , Sun CM , Calderaro J , Jeng YM , Hsiao LP , Lacroix L , Bougouin A , Moreira M , Lacroix G , Natario I , Adam J , Lucchesi C , Laizet YH , Toulmonde M , Burgess MA , Bolejack V , Reinke D , Wani KM , Wang WL , Lazar AJ , Roland CL , Wargo JA , Italiano A , Sautes-Fridman C , Tawbi HA , Fridman WH . B cells are associated with survival and immunotherapy response in sarcoma. Nature 2020; 577(7791): 556–560

[79] Li H , Lou L , Du J , Li M , Wen X , Zhang Y , Liu S , Zheng ZQ , Liu X . Multimodal profiling uncovers tertiary lymphoid structures as a critical determinant of immunotherapy response and prognosis in nasopharyngeal carcinoma. Oral Oncol 2025; 160: 107129

[80] Liu Y , Ye SY , He S , Chi DM , Wang XZ , Wen YF , Ma D , Nie RC , Xiang P , Zhou Y , Ruan ZH , Peng RJ , Luo CL , Wei PP , Lin GW , Zheng J , Cui Q , Cai MY , Yun JP , Dong J , Mai HQ , Xia X , Bei JX . Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma. Nat Commun 2024; 15(1): 7713

[81] Li JP , Wu CY , Chen MY , Liu SX , Yan SM , Kang YF , Sun C , Grandis JR , Zeng MS , Zhong Q . PD-1⁺CXCR5^–CD4⁺ Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma. J Immunother Cancer 2021; 9(7): e002101

[82] Lv J , Wei Y , Yin JH , Chen YP , Zhou GQ , Wei C , Liang XY , Zhang Y , Zhang CJ , He SW , He QM , Huang ZL , Guan JL , Shen JY , Li XM , Li JY , Li WF , Tang LL , Mao YP , Guo R , Sun R , Zheng YH , Zhou WW , Xiong KX , Wang SQ , Jin X , Liu N , Li GB , Kuang DM , Sun Y , Ma J . The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat Med 2023; 29(6): 1424–1436

[83] Chen JH , Nieman LT , Spurrell M , Jorgji V , Elmelech L , Richieri P , Xu KH , Madhu R , Parikh M , Zamora I , Mehta A , Nabel CS , Freeman SS , Pirl JD , Lu C , Meador CB , Barth JL , Sakhi M , Tang AL , Sarkizova S , Price C , Fernandez NF , Emanuel G , He J , Van Raay K , Reeves JW , Yizhak K , Hofree M , Shih A , Sade-Feldman M , Boland GM , Pelka K , Aryee MJ , Mino-Kenudson M , Gainor JF , Korsunsky I , Hacohen N . Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy. Nat Immunol 2024; 25(4): 644–658

[84] Magen A , Hamon P , Fiaschi N , Soong BY , Park MD , Mattiuz R , Humblin E , Troncoso L , D’Souza D , Dawson T , Kim J , Hamel S , Buckup M , Chang C , Tabachnikova A , Schwartz H , Malissen N , Lavin Y , Soares-Schanoski A , Giotti B , Hegde S , Ioannou G , Gonzalez-Kozlova E , Hennequin C , Le Berichel J , Zhao Z , Ward SC , Fiel I , Kou B , Dobosz M , Li L , Adler C , Ni M , Wei Y , Wang W , Atwal GS , Kundu K , Cygan KJ , Tsankov AM , Rahman A , Price C , Fernandez N , He J , Gupta NT , Kim-Schulze S , Gnjatic S , Kenigsberg E , Deering RP , Schwartz M , Marron TU , Thurston G , Kamphorst AO , Merad M . Intratumoral dendritic cell-CD4⁺ T helper cell niches enable CD8⁺ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat Med 2023; 29(6): 1389–1399

[85] Espinosa-Carrasco G , Chiu E , Scrivo A , Zumbo P , Dave A , Betel D , Kang SW , Jang HJ , Hellmann MD , Burt BM , Lee HS , Schietinger A . Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell 2024; 42(7): 1202–1216. e8

[86] Ma Y , Chen X , Wang A , Zhao H , Lin Q , Bao H , Zhang Y , Hong S , Tang W , Huang Y , Yang Y , Wu X , Shao Y , Fang W , Zhang L . Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma. J Immunother Cancer 2021; 9(3): e002014

[87] You R , Zou X , Ding X , Zhang WJ , Zhang MX , Wang X , Xu HS , Liu YL , Ouyang YF , Duan CY , Gu CM , Wang ZQ , Liu YP , Hua YJ , Huang PY , Chen MY . Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma. Med 2022; 3(10): 664–681.e6

[88] Wang S , Wu CY , He MM , Yong JX , Chen YX , Qian LM , Zhang JL , Zeng ZL , Xu RH , Wang F , Zhao Q . Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer. Nat Commun 2024; 15(1): 1515

[89] Xu L , Ma Y , Fang C , Peng Z , Gao F , Moll JM , Qin S , Yu Q , Hou Y , Kristiansen K , Fang W , Brix S , Zhang L . Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma. Front Oncol 2022; 12: 953884

[90] Even C , Wang HM , Li SH , Ngan RK , Dechaphunkul A , Zhang L , Yen CJ , Chan PC , Chakrabandhu S , Ma BBY , Tanasanvimon S , Lee VHF , Lou PJ , Li Z , Spira AI , Sukari A , Guigay J , McCune S , Gonzalez-Maffe J , Szpakowski S , Yao Y , Liang H , Mataraza J , Sechaud R , Manenti L , Lim DW . Phase II, randomized study of spartalizumab (PDR001), an anti-PD-1 antibody, versus chemotherapy in patients with recurrent/metastatic nasopharyngeal cancer. Clin Cancer Res 2021; 27(23): 6413–6423

[91] Wang K , Zhu L , Gong H , Huang K , Luo H , Yu W , Yi B , Liang Y . ANXA6 expression as a potential indicator of tumor diagnosis, metastasis and immunity in nasopharyngeal carcinoma. Int J Biol Macromol 2024; 283(Pt 4): 137809

[92] Liu Z , He J , Hu X . Ferroptosis regulators related scoring system by Gaussian finite mixture model to predict prognosis and immunotherapy efficacy in nasopharyngeal carcinoma. Front Genet 2022; 13: 975190

[93] Liu Z , He J , Han J , Yang J , Liao W , Chen N . m⁶A regulators mediated methylation modification patterns and tumor microenvironment infiltration characterization in nasopharyngeal carcinoma. Front Immunol 2022; 12: 762243

[94] Tang S , Wu Z , Chen L , She L , Zuo W , Luo W , Zhang Y , Liang S , Liu G , He B , He J , Zhang N . Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngeal carcinoma. Front Immunol 2023; 14: 1258344

[95] Huang Z , Li Y , Liu Q , Chen X , Lin W , Wu W , Chen Z , Chen X , Pan Y , Qiu S . SPP1-mediated M2 macrophage polarization shapes the tumor microenvironment and enhances prognosis and immunotherapy guidance in nasopharyngeal carcinoma. Int Immunopharmacol 2025; 147: 113944

[96] Zhang L , MacIsaac KD , Zhou T , Huang PY , Xin C , Dobson JR , Yu K , Chiang DY , Fan Y , Pelletier M , Wang Y , Jaeger S , Krishnamurthy Radhakrishnan V , JeBailey L , Skewes-Cox P , Zhang J , Fang W , Huang Y , Zhao H , Zhao Y , Li E , Peng B , Huang A , Dranoff G , Hammerman PS , Engelman J , Bitter H , Zeng YX , Yao Y . Genomic analysis of nasopharyngeal carcinoma reveals TME-based subtypes. Mol Cancer Res 2017; 15(12): 1722–1732

[97] Sun Y , Liu Y , Chu H . Nasopharyngeal carcinoma subtype discovery via immune cell scores from tumor microenvironment. J Immunol Res 2023; 2023: 2242577

[98] Wang Y , Peng L , Wang F . m⁶A-mediated molecular patterns and tumor microenvironment infiltration characterization in nasopharyngeal carcinoma. Cancer Biol Ther 2024; 25(1): 2333590

[99] Lenoci D , Resteghini C , Serafini MS , Pistore F , Canevari S , Ma B , Cavalieri S , Alfieri S , Trama A , Licitra L , De Cecco L . Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities. Transl Res 2024; 265: 1–16

[100] Jiang P , Gu S , Pan D , Fu J , Sahu A , Hu X , Li Z , Traugh N , Bu X , Li B , Liu J , Freeman GJ , Brown MA , Wucherpfennig KW , Liu XS . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 2018; 24(10): 1550–1558

[101] Chen YP , Lv JW , Mao YP , Li XM , Li JY , Wang YQ , Xu C , Li YQ , He QM , Yang XJ , Lei Y , Shen JY , Tang LL , Chen L , Zhou GQ , Li WF , Du XJ , Guo R , Liu X , Zhang Y , Zeng J , Yun JP , Sun Y , Liu N , Ma J . Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses. Mol Cancer 2021; 20(1): 14

[102] Shao JY , Li YH , Gao HY , Wu QL , Cui NJ , Zhang L , Cheng G , Hu LF , Ernberg I , Zeng YX . Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer 2004; 100(6): 1162–1170

[103] Lam WKJ , Jiang P , Chan KCA , Cheng SH , Zhang H , Peng W , Tse OYO , Tong YK , Gai W , Zee BCY , Ma BBY , Hui EP , Chan ATC , Woo JKS , Chiu RWK , Lo YMD . Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc Natl Acad Sci USA 2018; 115(22): E5115–E5124

[104] Chan KCA , Woo JKS , King A , Zee BCY , Lam WKJ , Chan SL , Chu SWI , Mak C , Tse IOL , Leung SYM , Chan G , Hui EP , Ma BBY , Chiu RWK , Leung SF , van Hasselt AC , Chan ATC , Lo YMD . Analysis of plasma Epstein-Barr Virus DNA to screen for nasopharyngeal cancer. N Engl J Med 2017; 377(6): 513–522

[105] Qian X , Chen H , Tao Y . Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol 2023; 14: 1146898

[106] Xu JY , Wei XL , Ren C , Zhang Y , Hu YF , Li JY , Chen JL , Wang YQ , Han F , Wang FH . Association of plasma Epstein-Barr virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 immunotherapy. JAMA Netw Open 2022; 5(3): e220587

[107] Chen X , Wang W , Zou Q , Zhu X , Lin Q , Jiang Y , Sun Y , Shen L , Wang L , Zou G , Lin X , Lin S , Li M , Wang Y , Xu R , Ao R , Wang R , Lin H , Huang S , Xu T , Li W , Xia M , Xia Y , Wang Z , Li B , Li J , Hu C . Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study. Signal Transduct Target Ther 2024; 9(1): 148

[108] Lin S , Zhou H , Chen G , Xue J , Liu Q , Li J , Yang Y , Zhao Y , Bao H , Huang Y , Ma Y , Zhao H . Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy. BMC Cancer 2024; 24(1): 797

[109] Economopoulou P , Pantazopoulos A , Spathis A , Kotsantis I , Kyriazoglou A , Kavourakis G , Zakopoulou R , Chatzidakis I , Anastasiou M , Prevezanou M , Resteghini C , Licitra L , Bergamini C , Colombo E , Caspani F , Denaro N , Vecchio S , Bonomo P , Cossu Rocca M , Bertolini F , Ferrari D , Psyrri A , Bossi P . Immunotherapy in nonendemic nasopharyngeal carcinoma: real-world data from two nonendemic regions. Cells 2021; 11(1): 32

[110] Ma BBY , Lim WT , Goh BC , Hui EP , Lo KW , Pettinger A , Foster NR , Riess JW , Agulnik M , Chang AYC , Chopra A , Kish JA , Chung CH , Adkins DR , Cullen KJ , Gitlitz BJ , Lim DW , To KF , Chan KCA , Lo YMD , King AD , Erlichman C , Yin J , Costello BA , Chan ATC . Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742). J Clin Oncol 2018; 36(14): 1412–1418

[111] Holder AM , Dedeilia A , Sierra-Davidson K , Cohen S , Liu D , Parikh A , Boland GM . Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer 2024; 24(7): 498–512

[112] Zhang Q , Luo J , Wu S , Si H , Gao C , Xu W , Abdullah SE , Higgs BW , Dennis PA , van der Heijden MS , Segal NH , Chaft JE , Hembrough T , Barrett JC , Hellmann MD . Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov 2020; 10(12): 1842–1853

[113] Mayerhoefer ME , Materka A , Langs G , Haggstrom I , Szczypinski P , Gibbs P , Cook G . Introduction to radiomics. J Nucl Med 2020; 61(4): 488–495

[114] MaiHLiLXinXJiangZTangYHuangJLeiYChenLDongTZhongX. Prediction of immunotherapy response in nasopharyngeal carcinoma: a comparative study using MRI-based radiomics signature and programmed cell death ligand 1 expression score. Eur Radiol 2025; [Epub ahead of print] doi:10.1007/s00330-025-11350-5

[115] Zeng F , Ye Z , Zhou Q . CT-based peritumoral radiomics nomogram on prediction of response and survival to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2024; 150(2): 50

[116] Wang Y , Chen F , Ouyang Z , He S , Qin X , Liang X , Huang W , Wang R , Hu K . MRI-based deep learning and radiomics for predicting the efficacy of PD-1 inhibitor combined with induction chemotherapy in advanced nasopharyngeal carcinoma: a prospective cohort study. Transl Oncol 2025; 52: 102245

[117] Lin M , Zhang XL , You R , Liu YP , Cai HM , Liu LZ , Liu XF , Zou X , Xie YL , Zou RH , Zhang YN , Sun R , Feng WY , Wang HY , Tao GH , Li HJ , Huang WJ , Zhang C , Huang PY , Wang J , Zhao Q , Yang Q , Zhang HW , Liu T , Li HF , Jiang XB , Tang J , Gu YK , Yu T , Wang ZQ , Feng L , Kang TB , Zuo ZX , Chen MY . Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significance. Nat Commun 2023; 14(1): 610

[118] Swanton C , Bernard E , Abbosh C , Andre F , Auwerx J , Balmain A , Bar-Sagi D , Bernards R , Bullman S , DeGregori J , Elliott C , Erez A , Evan G , Febbraio MA , Hidalgo A , Jamal-Hanjani M , Joyce JA , Kaiser M , Lamia K , Locasale JW , Loi S , Malanchi I , Merad M , Musgrave K , Patel KJ , Quezada S , Wargo JA , Weeraratna A , White E , Winkler F , Wood JN , Vousden KH , Hanahan D . Embracing cancer complexity: hallmarks of systemic disease. Cell 2024; 187(7): 1589–1616

[119] Lin Z , Liu M , Xing W , Wang F , Zhang H , Wei X , Schmitthenner H , Xie X , Xia X , Yang J . A near-infrared fluorescence-enhancing plasmonic biosensing microarray identifies soluble PD-L1 and ICAM-1 as predictive checkpoint biomarkers for cancer immunotherapy. Biosens Bioelectron 2023; 240: 115633

[120] Wu YX , Xing S , Wang Y , Tian BY , Wu M , Wang XP , Huang Q , He X , Chen SL , Li XH , Zeng MS , Liu WL . Multiple TMA-aided CRISPR/Cas13a platform for highly sensitive detection of IL-15 to predict immunotherapeutic response in nasopharyngeal carcinoma. J Immunother Cancer 2023; 11(8): e006552

[121] Hu B , Yang XR , Xu Y , Sun YF , Sun C , Guo W , Zhang X , Wang WM , Qiu SJ , Zhou J , Fan J . Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 2014; 20(23): 6212–6222

[122] Cao J , Chen Q , Bai X , Liu L , Ma W , Lin C , Lu F , Zhou T , Zhan J , Huang Y , Yang Y , Luo F , Zhao H . Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors. Ann Med 2023; 55(2): 2280002

[123] Song G , Wei Z , Pei Y , Liu Z , Min Y , Li H , Gao K , Ge J , Qing Y , Wei Y , Chen Y , Peng X . Harnessing the systemic immunoinflammatory index as a potential predictive tool for recurrent or metastatic nasopharyngeal carcinoma undergoing PD-L1 inhibitor. J Inflamm Res 2024; 17: 9169–9180

[124] Chen X , Liang W , Wu X , Wang Y , Hong Y , Xie M , Han R , Lin Z . A nomogram based on the SII3 and clinical indicators predicts survival in patients with nasopharyngeal carcinoma treated with PD-1 inhibitors. Medicine (Baltimore) 2024; 103(19): e38017

[125] Chen Y , Chen D , Wang R , Xie S , Wang X , Huang H . Development and validation of a nomogram to predicting the efficacy of PD-1/PD-L1 inhibitors in patients with nasopharyngeal carcinoma. Clin Transl Oncol 2024; 26(10): 2601–2607

[126] Mezquita L , Auclin E , Ferrara R , Charrier M , Remon J , Planchard D , Ponce S , Ares LP , Leroy L , Audigier-Valette C , Felip E , Zeron-Medina J , Garrido P , Brosseau S , Zalcman G , Mazieres J , Caramela C , Lahmar J , Adam J , Chaput N , Soria JC , Besse B . Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 2018; 4(3): 351–357

[127] Min Y , Liu X , Wei Z , Song G , Li Y , Gao K , Liu Z , Pei Y , Li H , Ge J , Qing Y , Wei Y , Peng X . Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: results from the multicenter, single-arm, phase 2 study. Oral Oncol 2024; 159: 107028

[128] Xiao BJ , Sima XX , Chen G , Gulizeba H , Zhou T , Huang Y . Predictive and prognostic role of early apolipoprotein A-I alteration in recurrent or metastatic nasopharyngeal carcinoma patients treated with anti-PD-1 therapy. Cancer Med 2023; 12(16): 16918–16928

[129] Luo F , Cao J , Chen Q , Liu L , Yang T , Bai X , Ma W , Lin C , Zhou T , Zhan J , Huang Y , Yang Y , Zhao H , Zhang L . HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype. J Immunother Cancer 2024; 12(6): e008146

[130] Guo J , Yang Q , Jiang Q , Gu LW , Lin HX , Guo L . Integrating baseline nutritional and inflammatory parameters with post-treatment EBV DNA level to predict outcomes of patients with de novo metastatic nasopharyngeal carcinoma receiving chemotherapy combination PD-1 inhibitor. Nutrients 2023; 15(19): 4262

[131] Shang K , He Q , Xu X , Luo X , Zhao C , Liu L , Li Z , Li Y , Jin F . Thyroid dysfunction after intensity-modulated radiotherapy and PD-1 inhibitor treatment for locally advanced nasopharyngeal carcinoma. Ther Clin Risk Manag 2025; 21: 15–25

[132] Chen ZH , Zheng WH , Wu CF , Kou J , Yang XL , Lin L , Lv JW , Sun Y , Zhou GQ . Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response. BMC Med 2023; 21(1): 18

[133] Ali WAS , Huang X , Wu Y , Ma Y , Pan H , Liao J , Yang Z , Hong S , Yang Y , Huang Y , Zhao Y , Fang W , Zhao H , Zhang L . Pretreatment serum lactate dehydrogenase and metastases numbers as potential determinants of anti-PD-1 therapy outcome in nasopharyngeal carcinoma. Cancer Contr 2023; 30: 10732748221148912

[134] Zhang A , Zhong G , Wang L , Cai R , Han R , Xu C , Chen S , Sun P , Chen H . Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma. Cancer Cell Int 2021; 21(1): 518

[135] Liang L , Li Y , Hong Y , Ji T , Chen H , Lin Z . Nomogram based on liver function test indicators for survival prediction in nasopharyngeal carcinoma patients receiving PD-1 inhibitor therapy. Curr Oncol 2023; 30(8): 7189–7202

[136] Wu YX , Tian BY , Ou XY , Wu M , Huang Q , Han RK , He X , Chen SL . A novel model for predicting prognosis and response to immunotherapy in nasopharyngeal carcinoma patients. Cancer Immunol Immunother 2024; 73(1): 14

[137] Liu GY , Lu N , Bei WX , Li WZ , Liang H , Xia WX , Xiang YQ , Yao HR . Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor. Front Immunol 2023; 14: 1069010

[138] Yang W , Chen C , Ouyang Q , Han R , Sun P , Chen H . Machine learning models for predicting of PD-1 treatment efficacy in pan-cancer patients based on routine hematologic and biochemical parameters. Cancer Cell Int 2024; 24(1): 258

[139] Gopalakrishnan V , Helmink BA , Spencer CN , Reuben A , Wargo JA . The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell 2018; 33(4): 570–580

[140] Yu Z , Wang Q , Wang Z , Liu S , Xia T , Duan C , Liu Y , Ding X , Chen S , Yu T , You R , Chen M , Huang P . Lachnoclostridium intestinal flora is associated with immunotherapy efficacy in nasopharyngeal carcinoma. Head Neck 2025; 47(1): 269–281

[141] Hanahan D . Hallmarks of cancer: new dimensions. Cancer Discov 2022; 12(1): 31–46

[142] Yang L , Li A , Wang Y , Zhang Y . Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduct Target Ther 2023; 8(1): 35

[143] Battaglia TW , Mimpen IL , Traets JJH , van Hoeck A , Zeverijn LJ , Geurts BS , de Wit GF , Noe M , Hofland I , Vos JL , Cornelissen S , Alkemade M , Broeks A , Zuur CL , Cuppen E , Wessels L , van de Haar J , Voest E . A pan-cancer analysis of the microbiome in metastatic cancer. Cell 2024; 187(9): 2324–2335. e19

[144] Qiao H , Tan XR , Li H , Li JY , Chen XZ , Li YQ , Li WF , Tang LL , Zhou GQ , Zhang Y , Liang YL , He QM , Zhao Y , Huang SY , Gong S , Li Q , Ye ML , Chen KL , Sun Y , Ma J , Liu N . Association of intratumoral microbiota with prognosis in patients with nasopharyngeal carcinoma from 2 hospitals in China. JAMA Oncol 2022; 8(9): 1301–1309

[145] Zhou YQ , Jiang JX , He S , Li YQ , Cheng XX , Liu SQ , Wei PP , Guan XY , Ong CK , Wang VY , Luo CL , Bei JX . Epstein-Barr virus hijacks histone demethylase machinery to drive epithelial malignancy progression through KDM5B upregulation. Signal Transduct Target Ther 2025; 10(1): 83

[146] Wang L , Wang D , Zeng X , Zhang Q , Wu H , Liu J , Wang Y , Liu G , Pan Y . Exploration of spatial heterogeneity of tumor microenvironment in nasopharyngeal carcinoma via transcriptional digital spatial profiling. Int J Biol Sci 2023; 19(7): 2256–2269

[147] Jiang YZ , Ma D , Suo C , Shi J , Xue M , Hu X , Xiao Y , Yu KD , Liu YR , Yu Y , Zheng Y , Li X , Zhang C , Hu P , Zhang J , Hua Q , Zhang J , Hou W , Ren L , Bao D , Li B , Yang J , Yao L , Zuo WJ , Zhao S , Gong Y , Ren YX , Zhao YX , Yang YS , Niu Z , Cao ZG , Stover DG , Verschraegen C , Kaklamani V , Daemen A , Benson JR , Takabe K , Bai F , Li DQ , Wang P , Shi L , Huang W , Shao ZM . Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell 2019; 35(3): 428–440. e5

[148] Zhao S , Ma D , Xiao Y , Li XM , Ma JL , Zhang H , Xu XL , Lv H , Jiang WH , Yang WT , Jiang YZ , Zhang QY , Shao ZM . Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance. Oncologist 2020; 25(10): e1481–e1491

[149] Jiang YZ , Liu Y , Xiao Y , Hu X , Jiang L , Zuo WJ , Ma D , Ding J , Zhu X , Zou J , Verschraegen C , Stover DG , Kaklamani V , Wang ZH , Shao ZM . Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res 2021; 31(2): 178–186

[150] Liu Y , Zhu XZ , Xiao Y , Wu SY , Zuo WJ , Yu Q , Cao AY , Li JJ , Yu KD , Liu GY , Wu J , Sun T , Cui JW , Lv Z , Li HP , Zhu XY , Jiang YZ , Wang ZH , Shao ZM . Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: the FUTURE phase II umbrella clinical trial. Cell Res 2023; 33(5): 389–402

[151] Heeke S , Gay CM , Estecio MR , Tran H , Morris BB , Zhang B , Tang X , Raso MG , Rocha P , Lai S , Arriola E , Hofman P , Hofman V , Kopparapu P , Lovly CM , Concannon K , De Sousa LG , Lewis WE , Kondo K , Hu X , Tanimoto A , Vokes NI , Nilsson MB , Stewart A , Jansen M , Horvath I , Gaga M , Panagoulias V , Raviv Y , Frumkin D , Wasserstrom A , Shuali A , Schnabel CA , Xi Y , Diao L , Wang Q , Zhang J , Van Loo P , Wang J , Wistuba II , Byers LA , Heymach JV . Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell 2024; 42(2): 225–237. e5

[152] Hamidi H , Senbabaoglu Y , Beig N , Roels J , Manuel C , Guan X , Koeppen H , Assaf ZJ , Nabet BY , Waddell A , Yuen K , Maund S , Sokol E , Giltnane JM , Schedlbauer A , Fuentes E , Cowan JD , Kadel EE 3rd , Degaonkar V , Andreev-Drakhlin A , Williams P , Carter C , Gupta S , Steinberg E , Loriot Y , Bellmunt J , Grivas P , Rosenberg J , van der Heijden MS , Galsky MD , Powles T , Mariathasan S , Banchereau R . Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade. Cancer Cell 2024; 42(12): 2098–2112. e4

[153] Lv J , Chen Y , Zhou G , Qi Z , Tan KRL , Wang H , Lin L , Chen F , Zhang L , Huang X , Liu R , Xu S , Chen Y , Ma J , Chua MLK , Sun Y . Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat Commun 2019; 10(1): 3941

[154] Lv J , Xu LX , Li ZX , Lin L , Wu CF , Quan TQ , Zhen ZC , Li WF , Tang LL , Mao YP , Chen L , Guo R , Zhang LL , Ai XL , Wu SY , Hao MY , Wei D , Li JB , Ma J , Chen YP , Zhou GQ , Sun Y . Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: the EP-SEASON study. Cancer Cell 2024; 42(8): 1401–1414. e4

[155] Arvaniti E , Claassen M . Sensitive detection of rare disease-associated cell subsets via representation learning. Nat Commun 2017; 8(1): 14825

[156] Sun D , Guan X , Moran AE , Wu LY , Qian DZ , Schedin P , Dai MS , Danilov AV , Alumkal JJ , Adey AC , Spellman PT , Xia Z . Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. Nat Biotechnol 2022; 40(4): 527–538

[157] Nikolaou N , Salazar D , RaviPrakash H , Gonçalves M , Mulla R , Burlutskiy N , Markuzon N , Jacob E . A machine learning approach for multimodal data fusion for survival prediction in cancer patients. NPJ Precis Oncol 2025; 9(1): 128

[158] Liang F , Peng L , Wu Z , Giamas G , Stebbing J . Design and reporting of phase III oncology trials with prospective biomarker validation. J Natl Cancer Inst 2023; 115(2): 174–180

[159] Jiang S , Li H , Zhang L , Mu W , Zhang Y , Chen T , Wu J , Tang H , Zheng S , Liu Y , Wu Y , Luo X , Xie Y , Ren J . Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res 2025; 53(D1): D1670–D1676

RIGHTS & PERMISSIONS

Higher Education Press